CFD-d on keerulised instrumendid, millega kaasneb võimenduse tõttu suur risk kiiresti raha kaotada. 84% jaeinvestoritest kaotab selle pakkuja juures CFD-dega kaubeldes raha. Mõelge järele, kas mõistate CFD-de toimimise põhimõtet ja kas saate endale lubada riski rahast ilma jääda.

Scan to Download iOS&Android APP

Ost-müük BioCryst - BCRX CFD

8.44
0.47%
0.07
Madal: 8.35
Kõrge: 8.51
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Kokkuvõte
  • Ajaloolised andmed
  • Sündmused
  • Tuluaruanne
  • Bilanss
  • Rahavood
  • Omand
Kauplemistingimused
Hinnavahe 0.07
Pika positsiooni ööpäeva tasu

Long position overnight fee


Margin. Your investment $1,000.00
Üleöö tasu -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Mine platvormile
-0.024068%
Lühikese positsiooni ööpäeva tasu

Short position overnight fee


Margin. Your investment $1,000.00
Üleöö tasu 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Mine platvormile
0.001846%
Ööpäeva tasu aeg 21:00 (UTC)
Min kauplemise kogus 1
Valuuta USD
Tagatis 20%
Aktsiabörs United States of America
Kauplemise vahendustasu 0%

*Information provided by Capital.com

Võtmestatistika
Eelmine sulgemine* 8.48
Avatud* 8.42
Aastane muutus* -47.11%
Päeva ulatus* 8.35 - 8.51
52 nädala ulatus 7.61-18.00
Keskmine maht (10 päeva) 2.84M
Keskmine maht (3 kuud) 61.63M
Turukapitalisatsioon 1.60B
P/E suhtarv -100.00K
Ringluses olevad aktsiad 188.45M
Tulu 270.83M
EPS -1.33
Dividendid (% kasumist) N/A
Beeta 2.03
Järgmine tuluaruande kuupäev May 3, 2023

Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Sulgemishind Change (%) Avamishind High Low
Mar 27, 2023 8.44 -0.03 -0.35% 8.47 8.53 8.34
Mar 24, 2023 8.48 0.36 4.43% 8.12 8.53 8.07
Mar 23, 2023 8.09 0.15 1.89% 7.94 8.28 7.91
Mar 22, 2023 7.90 -0.15 -1.86% 8.05 8.20 7.89
Mar 21, 2023 8.13 0.14 1.75% 7.99 8.20 7.91
Mar 20, 2023 7.97 -0.10 -1.24% 8.07 8.10 7.91
Mar 17, 2023 8.05 0.01 0.12% 8.04 8.15 7.97
Mar 16, 2023 8.14 -0.07 -0.85% 8.21 8.40 8.13
Mar 15, 2023 8.34 0.21 2.58% 8.13 8.57 8.12
Mar 14, 2023 8.29 -0.14 -1.66% 8.43 8.57 8.22
Mar 13, 2023 8.29 0.11 1.34% 8.18 8.51 8.15
Mar 10, 2023 8.26 0.11 1.35% 8.15 8.27 7.79
Mar 9, 2023 8.17 -0.32 -3.77% 8.49 8.60 8.06
Mar 8, 2023 8.52 -0.08 -0.93% 8.60 8.65 8.36
Mar 7, 2023 8.63 -0.19 -2.15% 8.82 8.87 8.62
Mar 6, 2023 8.81 0.07 0.80% 8.74 8.81 8.64
Mar 3, 2023 8.75 -0.13 -1.46% 8.88 8.91 8.71
Mar 2, 2023 8.81 0.15 1.73% 8.66 8.87 8.59
Mar 1, 2023 8.79 -0.04 -0.45% 8.83 8.90 8.60
Feb 28, 2023 8.81 -0.17 -1.89% 8.98 9.10 8.74

BioCryst Events

Kellaaeg (UTC) (UTC) Riik Sündmus
No events scheduled
Vaadake kõiki sündmusi
  • Aastas
  • Kvartalis
2022 2021 2020 2019 2018
Kogutulu 270.827 157.17 17.812 48.835 20.653
Tulu 270.827 157.17 17.812 48.835 20.653
Kulud, Kokku 6.594 7.264 1.676 4.101 0.471
Brutokasum 264.233 149.906 16.136 44.734 20.182
Kogu tegevuskulu 419.262 279.052 194.58 148.29 114.873
Müük/Üldine/admin kulud, kokku 159.371 118.818 67.929 37.121 13.614
Uuringud ja arendus 253.297 208.808 122.964 107.068 84.888
Tulud majandustegevusest -148.435 -121.882 -176.768 -99.455 -94.22
Intressitulud (kulu), muud tulud, neto -95.948 -59.927 -6.046 -9.442 -7.032
Netotulu enne makse -244.383 -181.809 -182.814 -108.897 -101.252
Netotulu pärast makse -247.116 -184.062 -182.814 -108.897 -101.252
Netotulu enne erikulusid -247.116 -184.062 -182.814 -108.897 -101.252
Netotulu -247.116 -184.062 -182.814 -108.897 -101.252
Arvestatav tulu, v a erikulud -247.116 -184.062 -182.814 -108.897 -101.252
Arvestatav tulu, koos erikuludega -247.116 -184.062 -182.814 -108.897 -101.252
Jaotamisele kuuluv netotulu -247.116 -184.062 -182.814 -108.897 -101.252
Keskmine jaotamisele kuuluv aktsia kohta 185.908 179.117 167.267 115.6 103.185
Jaotatav EPS, v a erakorralised kulud -1.32924 -1.02761 -1.09295 -0.94202 -0.98127
Dividends per Share - Common Stock Primary Issue
Jaotamisele kuuluv normaal-EPS -1.32924 -1.23024 -1.08092 -0.94202 -0.82717
Erakorralised kulud kokku
Ootamatud kulutused (tulu) 0 -55.838 2.011 15.9
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
Kogutulu 79.545 75.827 65.532 49.923 47.158
Tulu 79.545 75.827 65.532 49.923 47.158
Kulud, Kokku 2.496 3.613 0.247 0.238 0.419
Brutokasum 77.049 72.214 65.285 49.685 46.739
Kogu tegevuskulu 125.856 93.272 100.254 99.88 43.497
Müük/Üldine/admin kulud, kokku 50.153 36.919 38.017 34.282 35.387
Uuringud ja arendus 73.207 52.74 61.99 65.36 63.529
Tulud majandustegevusest -46.311 -17.445 -34.722 -49.957 3.661
Intressitulud (kulu), muud tulud, neto -25.154 -23.553 -23.281 -23.96 -19.187
Netotulu enne makse -71.465 -40.998 -58.003 -73.917 -15.526
Netotulu pärast makse -71.541 -42.52 -58.859 -74.196 -17.779
Netotulu enne erikulusid -71.541 -42.52 -58.859 -74.196 -17.779
Netotulu -71.541 -42.52 -58.859 -74.196 -17.779
Arvestatav tulu, v a erikulud -71.541 -42.52 -58.859 -74.196 -17.779
Arvestatav tulu, koos erikuludega -71.541 -42.52 -58.859 -74.196 -17.779
Jaotamisele kuuluv netotulu -71.541 -42.52 -58.859 -74.196 -17.779
Keskmine jaotamisele kuuluv aktsia kohta 186.934 186.18 185.605 184.898 181.871
Jaotatav EPS, v a erakorralised kulud -0.38271 -0.22838 -0.31712 -0.40128 -0.09776
Dividends per Share - Common Stock Primary Issue 0 0 0
Jaotamisele kuuluv normaal-EPS -0.38271 -0.22838 -0.31712 -0.40128 -0.29732
Ootamatud kulutused (tulu) 0 -55.838
  • Aastas
  • Kvartalis
2021 2020 2019 2018 2017
Käibevarad kokku 566.136 323.8 164.345 114.352 125.391
Raha ja lühiajalised investeeringud 507.601 300.366 136.226 104.467 114.397
Raha ja ekvivalendid 504.389 272.127 114.172 26.731 50.282
Lühiajalised investeeringud 3.212 28.239 22.054 77.736 64.115
Laekumata arved, neto 29.413 8.646 22.146 4.293 6.117
Accounts Receivable - Trade, Net 29.413 8.646 22.146 4.293 6.117
Total Inventory 15.791 7.039 0 1.649
Prepaid Expenses 9.986 5.528 4.422 2.39 1.381
Other Current Assets, Total 3.345 2.221 1.551 1.553 3.496
Total Assets 588.151 334.715 175.282 146.841 178.259
Property/Plant/Equipment, Total - Net 15.186 10.915 10.937 9.135 9.546
Property/Plant/Equipment, Total - Gross 25.925 20.892 18.911 15.23 14.873
Accumulated Depreciation, Total -10.739 -9.977 -7.974 -6.095 -5.327
Long Term Investments 6.829 0 22.376 41.295
Other Long Term Assets, Total 0.978 2.027
Total Current Liabilities 103.718 105.654 92.335 69.477 74.836
Accounts Payable 27.808 18.713 13.988 7.769 6.337
Accrued Expenses 74.489 56.791 37.646 27.739 24.794
Notes Payable/Short Term Debt 0 30 29.561 29.121 28.682
Other Current Liabilities, Total 1.421 0.15 2.12 0.221 8.484
Total Liabilities 695.137 353.977 137.03 97.606 94.492
Total Long Term Debt 585.457 244.452 41.289 28.075 19.501
Long Term Debt 585.457 244.452 41.289 25.372 16.75
Capital Lease Obligations 2.703 2.751
Other Liabilities, Total 5.962 3.871 3.406 0.054 0.155
Total Equity -106.986 -19.262 38.252 49.235 83.767
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 1.843 1.769 1.541 1.101 0.984
Additional Paid-In Capital 1098.5 1002.41 877.3 780.4 714.869
Retained Earnings (Accumulated Deficit) -1207.5 -1023.44 -840.628 -731.969 -631.843
Other Equity, Total 0.177 0.003 0.039 -0.297 -0.243
Total Liabilities & Shareholders’ Equity 588.151 334.715 175.282 146.841 178.259
Total Common Shares Outstanding 184.35 176.883 154.082 110.063 98.411
Current Port. of LT Debt/Capital Leases 0 9.02 4.627 6.539
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Käibevarad kokku 511.714 566.136 252.743 265.802 273.771
Raha ja lühiajalised investeeringud 443.468 507.601 199.597 218.428 240.356
Raha ja ekvivalendid 395.504 504.389 199.597 210.314 226.902
Lühiajalised investeeringud 47.964 3.212 0 8.114 13.454
Laekumata arved, neto 36.415 29.413 26.212 27.62 18.386
Accounts Receivable - Trade, Net 36.415 29.413 26.212 27.62 18.386
Total Inventory 16.144 15.791 13.663 9.846 5.113
Prepaid Expenses 12.333 9.986 8.975 5.56 5.908
Other Current Assets, Total 3.354 3.345 4.296 4.348 4.008
Total Assets 527.72 588.151 265.763 277.284 284.431
Property/Plant/Equipment, Total - Net 16.006 15.186 13.02 11.482 10.66
Property/Plant/Equipment, Total - Gross 9.098 7.519 5.924 6.565
Accumulated Depreciation, Total -3.019 -2.626 -2.328 -2.111 -2.94
Total Current Liabilities 81.017 103.718 133.608 115.601 101.201
Accounts Payable 13.881 27.808 19.693 10.087 13.529
Accrued Expenses 65.665 74.489 83.313 74.963 57.267
Notes Payable/Short Term Debt 0 0 30 30 30
Other Current Liabilities, Total 1.471 1.421 0.602 0.551 0.405
Total Liabilities 691.935 695.137 412.807 383.359 359.419
Total Long Term Debt 604.461 585.457 274.164 263.658 254.335
Long Term Debt 604.461 585.457 274.164 263.658 254.335
Other Liabilities, Total 6.457 5.962 5.035 4.1 3.883
Total Equity -164.215 -106.986 -147.044 -106.075 -74.988
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 1.856 1.843 1.798 1.787 1.777
Additional Paid-In Capital 1115.44 1098.5 1040.77 1022.97 1010.78
Retained Earnings (Accumulated Deficit) -1281.7 -1207.5 -1189.72 -1130.92 -1087.73
Other Equity, Total 0.186 0.177 0.114 0.087 0.182
Total Liabilities & Shareholders’ Equity 527.72 588.151 265.763 277.284 284.431
Total Common Shares Outstanding 185.572 184.35 179.791 178.725 177.67
Long Term Investments 0 6.829
  • Aastas
  • Kvartalis
2021 2020 2019 2018 2017
Netotulu/algväärtus -184.062 -182.814 -108.897 -101.252 -65.782
Raha majandustegevusest -142.157 -135.108 -89.584 -92.565 -41.143
Raha majandustegevusest 0.777 0.748 0.724 0.77 0.704
Mittelikviidsed varad 33.004 20.083 19.461 11.447 14.608
Muutused tööjõus 8.124 26.875 -0.872 -3.53 9.327
Tulu investeeringutelt 15.804 -6.856 77.934 4.768 -64.642
Kapitalikulutused -2.385 -0.514 -0.343 -0.366 -0.328
Muud rahavood investeeringutelt, kokku 18.189 -6.342 78.277 5.134 -64.314
Rahavood investeeringutelt 359.668 300.589 99.098 62.504 135.703
Aktsiate emiteerimine (tagasiost), neto 65.794 110.542 79.621 56.252 135.581
Laenu väljastamine (kustutamine), neto 293.874 190.047 19.477 6.252 0.122
Rahaline kogumuutus 233.386 158.625 87.448 -25.293 29.918
Muutused valuutakursside kõikumisest 0.071
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -74.196 -184.062 -166.283 -107.482 -64.284
Cash From Operating Activities -77.8 -142.157 -109.698 -86.422 -61.011
Cash From Operating Activities 0.317 0.777 0.606 0.377 0.178
Non-Cash Items 28.634 33.004 62.615 35.809 16.52
Changes in Working Capital -32.555 8.124 -6.636 -15.126 -13.425
Cash From Investing Activities -38.472 15.804 26.924 19.177 14.673
Capital Expenditures -0.406 -2.385 -1.277 -0.912 -0.099
Other Investing Cash Flow Items, Total -38.066 18.189 28.201 20.089 14.772
Cash From Financing Activities 7.356 359.668 12.25 7.474 2.9
Issuance (Retirement) of Stock, Net 7.356 65.794 12.25 7.474 2.9
Net Change in Cash -108.876 233.386 -70.455 -59.686 -43.438
Foreign Exchange Effects 0.04 0.071 0.069 0.085
Issuance (Retirement) of Debt, Net 293.874 0
Investori nimi Investori liik Ringluse protsent Hoitud osakud Muutus osakutes Hoidmise kuupäev Hinnang käibele
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.5177 14167131 359744 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.9264 13052882 1132849 2022-12-31 LOW
Baker Bros. Advisors LP Hedge Fund 6.7449 12710818 0 2022-12-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.9044 11126861 1722614 2022-12-31 LOW
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 4.8023 9050000 0 2022-12-31 LOW
Fidelity Management & Research Company LLC Investment Advisor 3.1084 5857788 1330751 2022-12-31 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 2.8046 5285348 471576 2022-12-31 LOW
Fisher Investments Investment Advisor/Hedge Fund 2.3513 4431114 -732731 2022-12-31 LOW
RP Management, LLC Private Equity 2.0409 3846154 0 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8395 3466550 100706 2022-12-31 LOW
Artisan Partners Limited Partnership Investment Advisor 1.5274 2878427 228811 2022-12-31 LOW
BNP Paribas Asset Management USA, Inc. Investment Advisor 1.4181 2672382 562718 2022-12-31 LOW
Assenagon Asset Management S.A. Investment Advisor 1.3746 2590392 -25765 2022-12-31 HIGH
Fairmount Funds Management LLC Hedge Fund 1.3495 2543107 0 2022-12-31 HIGH
Victory Capital Management Inc. Investment Advisor/Hedge Fund 1.3444 2533584 -986647 2022-12-31 LOW
Two Sigma Investments, LP Hedge Fund 1.3185 2484819 -562152 2022-12-31 HIGH
PFM Health Sciences, LP Hedge Fund 1.1475 2162411 0 2022-12-31 MED
Woodline Partners LP Hedge Fund 1.0989 2070983 2070983 2022-12-31 HIGH
Janus Henderson Investors Investment Advisor/Hedge Fund 1.0878 2050026 2014048 2022-12-31 LOW
Point72 Asset Management, L.P. Hedge Fund 1.0552 1988627 1988627 2022-12-31 HIGH

Miks valida Capital.com? Meie numbrid räägivad iseenda eest.

Capital.com Group

500K+

Kauplejad

92K+

Igakuiste aktiivsete klientide arv

$53M+

Igakuine investeerimise maht

$30M+

Igakuiselt välja võetud

Kauplemiskalkulaator

Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).

Kauplemise vahendustasu
0
  • 1:1
Finantsvõimendus
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind

Close

Lühike Pikk

BioCryst Company profile

Ettevõttest BioCryst

BioCryst Pharmaceuticals, Inc. (BioCryst) on kommertsjärgus biotehnoloogiaettevõte, mis avastab väikemolekulaarsed ravimid. Ettevõte keskendub haruldaste haiguste suukaudsele ravile, mille puhul on olemas rahuldamata meditsiinilised vajadused ja kus ensüüm mängib haiguse bioloogilises kulgemises võtmerolli. ORLADEYO (berotralstat) on suukaudne, üks kord päevas manustatav ravim, mis on heaks kiidetud Ameerika Ühendriikides, Euroopa Liidus, Jaapanis ja Ühendkuningriigis päriliku angioödeemi (HAE) rünnakute ennetamiseks täiskasvanutel ja 12-aastastel ja vanematel pediaatrilistel patsientidel. BioCrystil on mitu käimasolevat arendusprogrammi, sealhulgas BCX9930, suukaudne D-faktori inhibiitor komplemendi poolt vahendatud haiguste raviks; BCX9250, aktiviiniretseptori sarnase kinaas-2 (ALK-2) inhibiitor fibrodysplasia ossificans progressiva raviks, ja Galidesivir, viirusevastane ravim Marburgi viirushaiguse ja kollapalaviku raviks. RAPIVAB (peramiviiri süsti) on viiruse neuraminidaasi inhibiitor gripi raviks.

Industry: Bio Therapeutic Drugs

4505 Emperor Blvd Ste 200
27703-8457

Tuluaruanne

  • Annual
  • Quarterly

Teised on vaadanud veel

US100

12,662.50 Price
-0.330% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0241%
Lühikese positsiooni ööpäeva tasu 0.0018%
Ööpäeva tasu aeg 21:00 (UTC)
Hinnavahe 1.8

XRP/USD

0.49 Price
+3.300% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0753%
Lühikese positsiooni ööpäeva tasu 0.0069%
Ööpäeva tasu aeg 21:00 (UTC)
Hinnavahe 0.00395

BTC/USD

26,975.40 Price
-0.770% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0616%
Lühikese positsiooni ööpäeva tasu 0.0137%
Ööpäeva tasu aeg 21:00 (UTC)
Hinnavahe 60.00

Gold

1,956.65 Price
+0.010% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0180%
Lühikese positsiooni ööpäeva tasu 0.0097%
Ööpäeva tasu aeg 21:00 (UTC)
Hinnavahe 0.30

Kas otsite jätkuvalt vahendajat, keda saab usaldada?

Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com

1. Looge ja kinnitage oma konto 2. Tee sissemakse 3. Alusta kauplemist